Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4454016
Max Phase: Preclinical
Molecular Formula: C32H50N10O6S
Molecular Weight: 702.88
Molecule Type: Unknown
Associated Items:
ID: ALA4454016
Max Phase: Preclinical
Molecular Formula: C32H50N10O6S
Molecular Weight: 702.88
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)c1nc2ccccc2s1
Standard InChI: InChI=1S/C32H50N10O6S/c1-18(2)17-24(41-29(47)23(13-14-26(34)44)40-28(46)22(38-19(3)43)10-6-7-15-33)30(48)39-21(11-8-16-37-32(35)36)27(45)31-42-20-9-4-5-12-25(20)49-31/h4-5,9,12,18,21-24H,6-8,10-11,13-17,33H2,1-3H3,(H2,34,44)(H,38,43)(H,39,48)(H,40,46)(H,41,47)(H4,35,36,37)/t21-,22-,23-,24-/m0/s1
Standard InChI Key: WQISNVQCRKRHME-ZJZGAYNASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 702.88 | Molecular Weight (Monoisotopic): 702.3636 | AlogP: 0.14 | #Rotatable Bonds: 22 |
Polar Surface Area: 277.37 | Molecular Species: BASE | HBA: 10 | HBD: 9 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.71 | CX Basic pKa: 11.93 | CX LogP: -1.63 | CX LogD: -6.06 |
Aromatic Rings: 2 | Heavy Atoms: 49 | QED Weighted: 0.03 | Np Likeness Score: -0.23 |
1. Damalanka VC, Han Z, Karmakar P, O'Donoghue AJ, La Greca F, Kim T, Pant SM, Helander J, Klefström J, Craik CS, Janetka JW.. (2019) Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology., 62 (2): [PMID:30571119] [10.1021/acs.jmedchem.8b01536] |
2. Damalanka VC, Wildman SA, Janetka JW.. (2019) Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin., 10 (9): [PMID:31803403] [10.1039/C9MD00234K] |
Source(1):